#METABOLOMICS WORKBENCH hormel101_20180717_163645_mwtab.txt DATATRACK_ID:1459 STUDY_ID:ST001022 ANALYSIS_ID:AN001677 PROJECT_ID:PR000683 VERSION 1 CREATED_ON July 19, 2018, 1:06 pm #PROJECT PR:PROJECT_TITLE Mayo Pilot and Feasibility: Characterization of metabolomics profile changes PR:PROJECT_TITLE during development of post-traumatic epilepsy PR:PROJECT_SUMMARY According to the report from the Centers for Disease Control and Prevention in PR:PROJECT_SUMMARY 2014, traumatic brain injury (TBI) accounts for 30% of all injury-related deaths PR:PROJECT_SUMMARY in the U.S. Developing epilepsy after severe head injury is as high as 40%-50% PR:PROJECT_SUMMARY in some settings. Importantly, many TBI victims develop epilepsy months or years PR:PROJECT_SUMMARY following the initial injury. However, it has not been fully identified how to PR:PROJECT_SUMMARY predict who will develop epilepsy and/or the underlying mechanism of post PR:PROJECT_SUMMARY traumatic epilesy (PTE) development. The main goal of this proposal is to PR:PROJECT_SUMMARY identify the metabolomics biomarker of TBI-induced epilepsy and to investigate PR:PROJECT_SUMMARY the underlying mechanism of the transition from TBI to PTE. To do so, we will PR:PROJECT_SUMMARY develop PTE using two TBI animal models: ferrous chloride injection model and PR:PROJECT_SUMMARY cortical undercut model. Once the brain damage is made, electroencephalogram PR:PROJECT_SUMMARY (EEG) and video monitoring will be performed to determine the onset point of PR:PROJECT_SUMMARY epilepsy. Then, metabolomics profile changes will be analyzed and compared PR:PROJECT_SUMMARY before and after PTE development. PR:INSTITUTE Mayo Clinic PR:LAST_NAME Su-youne PR:FIRST_NAME Chang PR:ADDRESS 200 1st Street SW Rochester, MN 55905, USA PR:EMAIL Chang.SuYoune@mayo.edu PR:PHONE 1-507-293-0511 #STUDY ST:STUDY_TITLE Characterization of metabolomics profile changes during development of ST:STUDY_TITLE post-traumatic epilepsy in Rat Brain Tissue (part-III) ST:STUDY_SUMMARY Characterize the metabolomics profile changes during progression of the ST:STUDY_SUMMARY transition from traumatic brain injury (TBI) to post-traumatic epilepsy (PTE). ST:STUDY_SUMMARY To do so, three experiments will be performed. PTE animal model will be ST:STUDY_SUMMARY developed using ferrous chloride injections. Metabolomics profile changes will ST:STUDY_SUMMARY be obtained before TBI, after TBI, and after PTE development These temporal ST:STUDY_SUMMARY changes in metabolomics profile during the course of PTE development will be ST:STUDY_SUMMARY collected. We will also collect cerebrospinal fluid (CSF) at each time point. In ST:STUDY_SUMMARY addition, we will collect the brain tissue from the center of injury, around the ST:STUDY_SUMMARY injury, and from the non-injured area for mass spectrometry. In this study, the ST:STUDY_SUMMARY rat brain tissue at end of study is analyzed. ST:INSTITUTE Mayo Clinic ST:LAST_NAME Su-youne ST:FIRST_NAME Chang ST:ADDRESS 200 1st Street SW Rochester, MN 55905, USA ST:EMAIL Chang.SuYoune@mayo.edu ST:PHONE 1-507-293-0511 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS 1 nC18-07sep17-001 Groups:C | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 2 nC18-07sep17-002 Groups:C | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 3 nC18-11sep17-003 Groups:C | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 4 nC18-11sep17-004 Groups:C | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 5 nC18-07sep17-005 Groups:S | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 6 nC18-07sep17-006 Groups:S | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 7 nC18-11sep17-007 Groups:S | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 8 nC18-11sep17-008 Groups:S | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 9 nC18-07sep17-009 Groups:F | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 10 nC18-07sep17-010 Groups:F | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 11 nC18-11sep17-011 Groups:F | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 12 nC18-11sep17-012 Groups:R | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 13 nC18-07sep17-013 Groups:C | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 14 nC18-07sep17-014 Groups:C | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 15 nC18-11sep17-015 Groups:C | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 16 nC18-11sep17-016 Groups:C | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 17 nC18-07sep17-017 Groups:S | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 18 nC18-07sep17-018 Groups:S | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 19 nC18-11sep17-019 Groups:S | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 20 nC18-11sep17-020 Groups:S | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 21 nC18-07sep17-021 Groups:F | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 22 nC18-07sep17-022 Groups:F | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 23 nC18-11sep17-023 Groups:F | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 24 nC18-11sep17-024 Groups:R | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 25 nC18-07sep17-025 Groups:S_inj | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 26 nC18-07sep17-026 Groups:S_inj | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 27 nC18-11sep17-027 Groups:S_inj | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 28 nC18-11sep17-028 Groups:S_inj | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 29 nC18-07sep17-029 Groups:F_inj | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 30 nC18-07sep17-030 Groups:F_inj | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 31 nC18-11sep17-031 Groups:F_inj | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 32 nC18-11sep17-032 Groups:R_inj | Tissues:Cortex chromatography=NC18 SUBJECT_SAMPLE_FACTORS 33 nC18-07sep17-033 Groups:S_inj | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 34 nC18-07sep17-034 Groups:S_inj | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 35 nC18-11sep17-035 Groups:S_inj | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 36 nC18-11sep17-036 Groups:S_inj | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 37 nC18-07sep17-037 Groups:F_inj | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 38 nC18-07sep17-038 Groups:F_inj | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 39 nC18-11sep17-039 Groups:F_inj | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 40 nC18-11sep17-040 Groups:R_inj | Tissues:Hippocampus chromatography=NC18 SUBJECT_SAMPLE_FACTORS 1 pC18-05sep17-001 Groups:C | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 2 pC18-05sep17-002 Groups:C | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 3 pC18-09sep17-003 Groups:C | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 4 pC18-09sep17-004 Groups:C | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 5 pC18-05sep17-005 Groups:S | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 6 pC18-05sep17-006 Groups:S | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 7 pC18-09sep17-007 Groups:S | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 8 pC18-09sep17-008 Groups:S | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 9 pC18-05sep17-009 Groups:F | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 10 pC18-05sep17-010 Groups:F | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 11 pC18-09sep17-011 Groups:F | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 12 pC18-09sep17-012 Groups:R | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 13 pC18-05sep17-013 Groups:C | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 14 pC18-05sep17-014 Groups:C | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 15 pC18-09sep17-015 Groups:C | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 16 pC18-09sep17-016 Groups:C | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 17 pC18-05sep17-017 Groups:S | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 18 pC18-05sep17-018 Groups:S | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 19 pC18-09sep17-019 Groups:S | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 20 pC18-09sep17-020 Groups:S | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 21 pC18-05sep17-021 Groups:F | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 22 pC18-05sep17-022 Groups:F | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 23 pC18-09sep17-023 Groups:F | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 24 pC18-09sep17-024 Groups:R | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 25 pC18-05sep17-025 Groups:S_inj | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 26 pC18-05sep17-026 Groups:S_inj | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 27 pC18-09sep17-027 Groups:S_inj | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 28 pC18-09sep17-028 Groups:S_inj | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 29 pC18-05sep17-029 Groups:F_inj | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 30 pC18-05sep17-030 Groups:F_inj | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 31 pC18-09sep17-031 Groups:F_inj | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 32 pC18-09sep17-032 Groups:R_inj | Tissues:Cortex chromatography=PC18 SUBJECT_SAMPLE_FACTORS 33 pC18-05sep17-033 Groups:S_inj | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 34 pC18-05sep17-034 Groups:S_inj | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 35 pC18-09sep17-035 Groups:S_inj | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 36 pC18-09sep17-036 Groups:S_inj | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 37 pC18-05sep17-037 Groups:F_inj | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 38 pC18-05sep17-038 Groups:F_inj | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 39 pC18-09sep17-039 Groups:F_inj | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 40 pC18-09sep17-040 Groups:R_inj | Tissues:Hippocampus chromatography=PC18 SUBJECT_SAMPLE_FACTORS 1 nhilic-07sep17-001 Groups:C | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 2 nhilic-07sep17-002 Groups:C | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 3 nhilic-09sep17-003 Groups:C | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 4 nhilic-09sep17-004 Groups:C | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 5 nhilic-07sep17-005 Groups:S | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 6 nhilic-07sep17-006 Groups:S | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 7 nhilic-09sep17-007 Groups:S | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 8 nhilic-09sep17-008 Groups:S | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 9 nhilic-07sep17-009 Groups:F | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 10 nhilic-07sep17-010 Groups:F | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 11 nhilic-09sep17-011 Groups:F | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 12 nhilic-09sep17-012 Groups:R | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 13 nhilic-07sep17-013 Groups:C | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 14 nhilic-07sep17-014 Groups:C | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 15 nhilic-09sep17-015 Groups:C | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 16 nhilic-09sep17-016 Groups:C | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 17 nhilic-07sep17-017 Groups:S | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 18 nhilic-07sep17-018 Groups:S | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 19 nhilic-09sep17-019 Groups:S | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 20 nhilic-09sep17-020 Groups:S | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 21 nhilic-07sep17-021 Groups:F | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 22 nhilic-07sep17-022 Groups:F | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 23 nhilic-09sep17-023 Groups:F | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 24 nhilic-09sep17-024 Groups:R | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 25 nhilic-07sep17-025 Groups:S_inj | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 26 nhilic-07sep17-026 Groups:S_inj | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 27 nhilic-09sep17-027 Groups:S_inj | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 28 nhilic-09sep17-028 Groups:S_inj | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 29 nhilic-07sep17-029 Groups:F_inj | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 30 nhilic-07sep17-030 Groups:F_inj | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 31 nhilic-09sep17-031 Groups:F_inj | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 32 nhilic-09sep17-032 Groups:R_inj | Tissues:Cortex chromatography=nhilic SUBJECT_SAMPLE_FACTORS 33 nhilic-07sep17-033 Groups:S_inj | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 34 nhilic-07sep17-034 Groups:S_inj | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 35 nhilic-09sep17-035 Groups:S_inj | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 36 nhilic-09sep17-036 Groups:S_inj | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 37 nhilic-07sep17-037 Groups:F_inj | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 38 nhilic-07sep17-038 Groups:F_inj | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 39 nhilic-09sep17-039 Groups:F_inj | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 40 nhilic-09sep17-040 Groups:R_inj | Tissues:Hippocampus chromatography=nhilic SUBJECT_SAMPLE_FACTORS 1 philic-06sep17-001 Groups:C | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 2 philic-06sep17-002 Groups:C | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 3 philic-08sep17-003 Groups:C | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 4 philic-08sep17-004 Groups:C | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 5 philic-06sep17-005 Groups:S | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 6 philic-06sep17-006 Groups:S | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 7 philic-08sep17-007 Groups:S | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 8 philic-08sep17-008 Groups:S | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 9 philic-06sep17-009 Groups:F | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 10 philic-06sep17-010 Groups:F | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 11 philic-08sep17-011 Groups:F | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 12 philic-08sep17-012 Groups:R | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 13 philic-06sep17-013 Groups:C | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 14 philic-06sep17-014 Groups:C | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 15 philic-08sep17-015 Groups:C | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 16 philic-08sep17-016 Groups:C | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 17 philic-06sep17-017 Groups:S | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 18 philic-06sep17-018 Groups:S | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 19 philic-08sep17-019 Groups:S | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 20 philic-08sep17-020 Groups:S | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 21 philic-06sep17-021 Groups:F | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 22 philic-06sep17-022 Groups:F | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 23 philic-08sep17-023 Groups:F | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 24 philic-08sep17-024 Groups:R | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 25 philic-06sep17-025 Groups:S_inj | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 26 philic-06sep17-026 Groups:S_inj | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 27 philic-08sep17-027 Groups:S_inj | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 28 philic-08sep17-028 Groups:S_inj | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 29 philic-06sep17-029 Groups:F_inj | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 30 philic-06sep17-030 Groups:F_inj | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 31 philic-08sep17-031 Groups:F_inj | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 32 philic-08sep17-032 Groups:R_inj | Tissues:Cortex chromatography=philic SUBJECT_SAMPLE_FACTORS 33 philic-06sep17-033 Groups:S_inj | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 34 philic-06sep17-034 Groups:S_inj | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 35 philic-08sep17-035 Groups:S_inj | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 36 philic-08sep17-036 Groups:S_inj | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 37 philic-06sep17-037 Groups:F_inj | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 38 philic-06sep17-038 Groups:F_inj | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 39 philic-08sep17-039 Groups:F_inj | Tissues:Hippocampus chromatography=philic SUBJECT_SAMPLE_FACTORS 40 philic-08sep17-040 Groups:R_inj | Tissues:Hippocampus chromatography=philic #COLLECTION CO:COLLECTION_SUMMARY "Rats will either be controls, injected with saline, or injected with ferrous CO:COLLECTION_SUMMARY chloride to influence PTE. Also one of the ferrous chloride treated rats was CO:COLLECTION_SUMMARY repeated (R_no_cx, R_no_hp, R_inj_cx, R_inj_hp). Study Groupings: C_no_cx = CO:COLLECTION_SUMMARY control, no injections, cortex tissue C_no_hp = control, no injections, CO:COLLECTION_SUMMARY hippocampus tissue S_no_cx = saline treated, cortex tissue not near injection CO:COLLECTION_SUMMARY site S_no_hp = saline treated, hippocampus tissue not near injection site CO:COLLECTION_SUMMARY S_inj_cx = saline treated, cortex tissue at injection site S_inj_hp = saline CO:COLLECTION_SUMMARY treated, hippocampus tissue at injection site F_no_cx = ferrous chloride CO:COLLECTION_SUMMARY treated, cortex tissue not near injection site F_no_hp = ferrou chloride CO:COLLECTION_SUMMARY treated, hippocampus tissue not near injection site F_inj_cx = ferrous chloride CO:COLLECTION_SUMMARY treated, cortex tissue at injection site F_inj_hp = ferrous chloride treated, CO:COLLECTION_SUMMARY hippocampus tissue at injection site Experimental Flow Day0: baseline pre TBI. CO:COLLECTION_SUMMARY Blood and CSF collected Day1: Surgery for TBI. Injections of Ferrous Cloride or CO:COLLECTION_SUMMARY Saline Day2: CSF collected Weeks1-3: montoring to determine PTE starting point. CO:COLLECTION_SUMMARY Blood and CSF collected 1 Month: montoring of PTE. Blood and CSF collected 2 CO:COLLECTION_SUMMARY Month: Animal is euthanized and blood, CSF, and tissue harvested CO:SAMPLE_TYPE Brain #TREATMENT TR:TREATMENT_SUMMARY "Rats will either be controls, injected with saline, or injected with ferrous TR:TREATMENT_SUMMARY chloride to influence PTE. Trauma-Induced Epilepsy Model: Ferrous chloride TR:TREATMENT_SUMMARY injection model: Ferrous chloride solution (5 μl of 100 mM with saline) will be TR:TREATMENT_SUMMARY injected at a rate of 0.5 μl/min through a Hamilton micro-syringe controlled by TR:TREATMENT_SUMMARY a micro-pump (UMP3, WPI, FL). Once the ferrous chloride solution injection is TR:TREATMENT_SUMMARY completed, the syringe will remain in position for 5 minutes, and then it will TR:TREATMENT_SUMMARY be removed slowly. The burr holes will be closed with light-curing dental TR:TREATMENT_SUMMARY cement. The dose of ferrous chloride injection was determined from prior TR:TREATMENT_SUMMARY published reports from mouse, rat, and cat. They all used 100 mM ferrous TR:TREATMENT_SUMMARY chloride aqueous solution and volumes were various: 1 μl for mouse,14 5 μl for TR:TREATMENT_SUMMARY rat (200-300 g),15 and 10 μl for cat (2-4 Kg).15 Video monitoring: The use of TR:TREATMENT_SUMMARY 24 x 7 video monitoring and review means that we do not have to rely on the rats TR:TREATMENT_SUMMARY having seizures during daily rounding or at some other time when a human happens TR:TREATMENT_SUMMARY to be present in the home cage. Normally, the video will be watched in time TR:TREATMENT_SUMMARY lapse, fast-forward mode to scan for potential seizures. The reviewer can then TR:TREATMENT_SUMMARY stop the video, rewind and watch the behavioral episode in real-time or slow TR:TREATMENT_SUMMARY motion to determine whether a seizure actually occurred. Behavioral seizures TR:TREATMENT_SUMMARY will be identified by any combination or sequence of the following: loss of TR:TREATMENT_SUMMARY postural control (opisthotonus), tonic flexion or extension of limbs or TR:TREATMENT_SUMMARY head/neck, and clonic movements of limbs or head/neck. Often, behavioral TR:TREATMENT_SUMMARY seizures in rats may be accompanied by drooling, urination and facial twitches, TR:TREATMENT_SUMMARY although these may not always be observable on video. In addition, seizures will TR:TREATMENT_SUMMARY likely be followed by a postictal phase, which may include a period of running, TR:TREATMENT_SUMMARY jumping and general agitation. Video monitoring cannot detect subclinical or TR:TREATMENT_SUMMARY electrographic seizures (i.e., seizures without a behavioral component). Video TR:TREATMENT_SUMMARY will be reviewed in this way for each rat in order to establish that a cortical TR:TREATMENT_SUMMARY injured rat does indeed have epilepsy, to establish the “typical seizure” TR:TREATMENT_SUMMARY pattern in each rat, and to help establish a seizure frequency baseline, TR:TREATMENT_SUMMARY although it is understood that video monitoring alone might occasionally miss a TR:TREATMENT_SUMMARY seizure. EEG monitoring: To prevent imaging distortion and ferromagnetic TR:TREATMENT_SUMMARY interference, graphite carbon electrodes will be fabricated and/or purchased. A TR:TREATMENT_SUMMARY total of five electrodes will be implanted for EEG monitoring on the skull. EEG TR:TREATMENT_SUMMARY will be monitored with the Open EPhys System.18 While EEG recording, EEG TR:TREATMENT_SUMMARY electrodes will be connected to wires attached to the ceiling of a cage. In TR:TREATMENT_SUMMARY trauma-induced epilepsy rats, spontaneous neural activity will be recorded using TR:TREATMENT_SUMMARY a wide bandwidth (0-9 kHz) recording system. Post-analysis will be used to TR:TREATMENT_SUMMARY identify epilepsy signals." #SAMPLEPREP SP:SAMPLEPREP_SUMMARY "large scale profiling of rat cortex and hippocampus brian tissue. The brain SP:SAMPLEPREP_SUMMARY tissue and CSF will be collected for mass spectrometry. To prepare samples, SP:SAMPLEPREP_SUMMARY proteins will be removed from collected dialysates by adding cold methanol:water SP:SAMPLEPREP_SUMMARY (8:1, v/v) mixture containing 5.0 μg internal standard (IS), myristic-d27 acid, SP:SAMPLEPREP_SUMMARY at ambient temperature. Samples will be vortexed for 1 min, incubated on ice for SP:SAMPLEPREP_SUMMARY 15 min, and then centrifuged. The supernatant will be completely dried in a SP:SAMPLEPREP_SUMMARY SpeedVac, and the lyophilized sample will be subsequently methoxiaminated using SP:SAMPLEPREP_SUMMARY 20 μl of a 20 mg/ml solution of methoxyamine hydrochloride in pyridine at 30°C SP:SAMPLEPREP_SUMMARY for 90 min and derivatized using 80 μL of SP:SAMPLEPREP_SUMMARY N-methyl-N-trimethylsilyltrifluoroacetamide with 1% trimethylchloro-silane SP:SAMPLEPREP_SUMMARY (MSTFA + 1% TMCS, Pierce) at 37°C for 30 min." #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE HILIC CH:INSTRUMENT_NAME Agilent 1290 Infinity CH:COLUMN_NAME Waters Acquity BEH Amide (150 x 2.1mm, 1.7um) #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:MS_COMMENTS - MS:INSTRUMENT_NAME Agilent 6550 QTOF MS:INSTRUMENT_TYPE QTOF MS:MS_TYPE ESI MS:ION_MODE NEGATIVE MS:MS_RESULTS_FILE ST001022_AN001677_Results.txt UNITS:intensity #END